305 related articles for article (PubMed ID: 33813375)
1. New Approaches in Targeted Therapy for Medulloblastoma in Children.
Maier H; Dalianis T; Kostopoulou ON
Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
5. Postoperative radiotherapy for paediatric medulloblastoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e381. PubMed ID: 27523622
[No Abstract] [Full Text] [Related]
6. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
7. Molecular progression of SHH-activated medulloblastomas.
Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Sievers P; Meyer J; Schrimpf D; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; von Deimling A; Kool M
Acta Neuropathol; 2019 Aug; 138(2):327-330. PubMed ID: 31030238
[No Abstract] [Full Text] [Related]
8. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
Kumar R; Smith KS; Deng M; Terhune C; Robinson GW; Orr BA; Liu APY; Lin T; Billups CA; Chintagumpala M; Bowers DC; Hassall TE; Hansford JR; Khuong-Quang DA; Crawford JR; Bendel AE; Gururangan S; Schroeder K; Bouffet E; Bartels U; Fisher MJ; Cohn R; Partap S; Kellie SJ; McCowage G; Paulino AC; Rutkowski S; Fleischhack G; Dhall G; Klesse LJ; Leary S; Nazarian J; Kool M; Wesseling P; Ryzhova M; Zheludkova O; Golanov AV; McLendon RE; Packer RJ; Dunham C; Hukin J; Fouladi M; Faria CC; Pimentel J; Walter AW; Jabado N; Cho YJ; Perreault S; Croul SE; Zapotocky M; Hawkins C; Tabori U; Taylor MD; Pfister SM; Klimo P; Boop FA; Ellison DW; Merchant TE; Onar-Thomas A; Korshunov A; Jones DTW; Gajjar A; Ramaswamy V; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):807-821. PubMed ID: 33502920
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
13. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
15. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O; Győrffy B
Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
[TBL] [Abstract][Full Text] [Related]
16. Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines.
Holthouse DJ; Dallas PB; Ford J; Fabian V; Murch AR; Watson M; Wong G; Bertram C; Egli S; Baker DL; Kees UR
Neuropathology; 2009 Aug; 29(4):398-409. PubMed ID: 19077040
[TBL] [Abstract][Full Text] [Related]
17. The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases.
Wu T; Qu PR; Zhang S; Li SW; Zhang J; Wang B; Liu P; Li CD; Zhao F
Sci Rep; 2020 Jun; 10(1):9769. PubMed ID: 32555264
[TBL] [Abstract][Full Text] [Related]
18. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
19. CTGF expression is indicative of better survival rates in patients with medulloblastoma.
Cruzeiro GAV; Lira RCP; de Almeida Magalhães T; Scrideli CA; Valera ET; Baumgartner M; Tone LG
Cancer Gene Ther; 2020 May; 27(5):378-382. PubMed ID: 31073205
[TBL] [Abstract][Full Text] [Related]
20. Molecular Classification of Medulloblastoma.
Kijima N; Kanemura Y
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]